Skip to cookie consent Skip to main content

Research Spotlight: Improving the Efficacy of Immune Checkpoint Blockers in Pancreatic Cancer

Contributor: Rakesh Jain, PhD
Rakesh Jain, PhD
Rakesh Jain, PhD

Rakesh Jain, PhD, director of the Edwin Steele Laboratories for Tumor Biology in the Department of Radiation Oncology at Massachusetts General Hospital and Andrew Werk Professor of Radiation Oncology at Harvard Medical School, is senior and corresponding author of a paper published in the Journal for ImmunoTherapy of Cancer, “IL-1β Blockade Prevents Cardiotoxicity and Improves Efficacy of Immune Checkpoint Blockers and Chemotherapy against Pancreatic Cancer in Mice with Obesity.

Q: How would you summarize your study for a lay audience?

Immune checkpoint blockers (ICBs) have revolutionized cancer therapy, yet they remain largely ineffective in treating pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. ICBs can cause severe immune-related adverse events (irAEs), including fatal cardiac toxicity known as myocarditis, but their causes are unclear.

Obesity is a risk factor in PDAC that may modulate ICB efficacy. Here, we found that following chemo and ICB therapy, obese mice with pancreatic cancer exhibited myocarditis and had an elevated serum IL-1β levels.

Q: What question were you investigating?

What are the mechanisms behind the failure of immune checkpoint therapy (ICB) in patients with PDAC, the most common form of pancreatic cancer, and how does obesity affect the risk of immune-related adverse events (irAEs)?

Q: What methods or approach did you use?

We employed a clinically relevant mouse model of pancreatic ductal adenocarcinoma (PDAC) and irAEs that incorporated three key features of the human disease: 

(1) High-fat diet-induced obesity
(2) Tumor growing in the pancreas
(3) A therapeutic regimen combining the standard of care chemotherapy (FOLFIRINOX) with dual ICB (anti-PD-1 and anti-CTLA-4 antibodies).

Our model recapitulated key irAEs associated with ICB therapy in the context of obesity, without relying on genetic deletion of checkpoint molecules, or subcutaneous tumor implantation—approaches commonly used in previous studies that may introduce confounding factors.

Q: What did you find?

Following chemoimmunotherapy, obese mice exhibited myocarditis associated with elevated serum IL-1β levels.

Blocking IL-1β prevented myocarditis, reduced cardiac fibrosis, and enhanced the anti-tumor efficacy of combined chemotherapy and dual ICBs, which led to a significant improvement in overall survival in PDAC-bearing obese mice.

Q: What are the implications?

Our study provides compelling data and the rationale to test an FDA-approved anti-IL-1 antibody in combination with chemotherapy and dual ICB in PDAC patients with obesity.

Q: What are the next steps?

ICB has failed to induce benefits in PDAC patients, and obesity may promote ICB resistance. 

The next step is to start a clinical trial of an anti-IL-1β agent with FOLFIRINOX and anti-PD-1 and anti-CTLA-4 dual ICB therapy for PDAC patients with obesity.

Authorship: In addition to Jain, Mass General Brigham authors include Nilesh P. Talele, Heena Kumra, Igor L. Gomes-Santos, William W. Ho, Patrick Andersson, Marie Siwicki, Peigen Huang, Dan G. Duda, Mikael J. Pittet and Dai Fukumura.

Paper cited: Talele NP, et al “IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity” Journal for ImmunoTherapy of Cancer 2025. DOI: 10.1136/jitc-2024-011404 

Funding: This work was supported by Jain’s grants from NIH (R01CA269672, R01-CA259253, R01-CA208205, U01-CA261842, and U01-CA 224348, Outstanding Investigator Award R35-CA197743), the National Foundation for Cancer Research, Jane’s Trust Foundation, Niles Albright Research Foundation and Harvard Ludwig Cancer Center; Pittet’s grants from ISREC Foundation and NIH (P01-CA240239); Fukumura’s grants from NIH (R01-CA208205, R0-NS100808, R01-NS118929, and R01-MH110438), Duda’s grants from NIH (R01CA260872, R01CA254351, and R01CA24744). Telele’s Merck-CRI Irvington Fellowship and Kumra’s the Jane’s Trust Foundation Fellowship.

Disclosures: Jain received consultant fees from DynamiCure, SynDevRx; owns equity in Accurius, Enlight, SynDevRx; and served on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund; and received a grant from Sanofi. Duda received research grants from Exelixis, BMS, Bayer, and Surface Oncology. Pittet has served as a consultant for Acthera, ImmuneOncia, LegoChemBio, MaxiVax, Molecular Partners, Merck, Third Rock Ventures, UNIKUM, and Tidal. No funding or reagents from these companies were used in this study. The other authors have no competing interests to declare.

Media contact

Elizabeth Murphy
Program Director, External Communications

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.